Cluster number | C1 | C2 | C3 | C4 | C5 |
---|---|---|---|---|---|
Gout incident cases (n) | 551 | 53 | 26 | 235 | 45 |
Diabetes (DM) | |||||
Baseline, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 19 (42.2) |
Incident cases, n (%) | 81 (14.7) | 6 (11.3) | 2 (7.7) | 62 (26.4) | 8 (17.8) |
Total cases, n (%) | 81 (14.7) | 6 (11.3) | 2 (7.7) | 62 (26.4) | 27 (60.0) |
Follow-up time, mean ± SD* | 28.45 ± 8.62 | 25.55 ± 8.81 | 21.31 ± 10.16 | 25.63 ± 9.14 | 17.73 ± 11.24 |
Obesity | |||||
Baseline, n (%) | 0 (0) | 7 (13.2) | 3 (11.5) | 93 (39.6) | 17 (37.8) |
Incident cases, n (%) | 14 (2.5) | 0 (0) | 2 (7.7) | 7 (3.0) | 0 (0) |
Total cases, n (%) | 14 (2.5) | 7 (13.2) | 5 (19.2) | 100 (42.5) | 17 (37.8) |
Follow-up time, mean ± SD* | 29.22 ± 8.36 | 26.48 ± 8.64 | 22.22 ± 10.29 | 27.15 ± 9.01 | 23.46 ± 9.98 |
Dyslipidemia | |||||
Baseline, n (%) | 0 (0) | 11 (20.8) | 6 (23.1) | 113 (48.1) | 15 (33.3) |
Incident cases, n (%) | 54 (9.8) | 4 (7.5) | 3 (11.5) | 16 (6.8) | 8 (17.8) |
Total cases, n (%) | 54 (9.8) | 15 (28.3) | 9 (34.6) | 129 (54.8) | 23 (51.1) |
Follow-up time, mean ± SD* | 29.28 ± 8.36 | 26.59 ± 8.53 | 22.26 ± 10.31 | 27.51 ± 8.88 | 23.86 ± 9.76 |
Hypertension | |||||
Baseline, n (%) | 112 (20.3) | 18 (34.0) | 6 (23.1) | 79 (33.6) | 23 (51.1) |
Incident cases, n (%) | 201 (36.5) | 14 (26.4) | 10 (38.5) | 75 (31.9) | 11 (24.4) |
Total cases, n (%) | 313 (56.8) | 32 (60.3) | 16 (61.5) | 154 (65.5) | 34 (75.5) |
Follow-up time, mean ± SD* | 26.77 ± 8.62 | 23.28 ± 9.28 | 19.65 ± 9.83 | 24.19 ± 9.07 | 19.29 ± 9.64 |
Cardiovascular disease (CVD) | |||||
Baseline, n (%) | 0 (0) | 0 (0) | 26 (100) | 0 (0) | 4 (8.9) |
Incident cases, n (%) | 253 (45.9) | 24 (45.3) | NA | 119 (50.6) | 21 (46.7) |
Total cases, n (%) | 253 (45.9) | 24 (45.3) | 26 (100) | 119 (50.6) | 25 (55.5) |
Follow-up time, mean ± SD* | 27.27 ± 9.11 | 24.43 ± 9.15 | 18.01 ± 10.41 | 24.29 ± 9.71 | 20.98 ± 10.17 |
Kidney dysfunction and chronic kidney disease (CKD) | |||||
Baseline, n (%)^ | 0 (0) | 53 (100) | 3 (11.5) | 0 (0) | 7 (15.6) |
Incident cases, n (%) | 107 (19.4) | NA | 4 (15.4) | 49 (20.9) | 14 (31.1) |
Total cases, n (%) | 107 (19.4) | 53 (100) | 7 (26.9) | 49 (20.9) | 21 (46.6) |
Follow-up time, mean ± SD* | 28.03 ± 9.06 | 24.89 ± 9.47 | 21.34 ± 10.25 | 26.22 ± 9.31 | 22.37 ± 9.90 |
Pulmonary dysfunction (PD) and chronic obstructive pulmonary disease (COPD) | |||||
Baseline, n (%)^ | 86 (15.6) | 7 (13.2) | 4 (15.4) | 38 (16.2) | 10 (22.2) |
Incident cases, n (%) | 37 (6.7) | 4 (7.5) | 1 (3.8) | 19 (8.1) | 5 (11.1) |
Total cases, n (%) | 123 (22.3) | 11 (20.7) | 5 (19.2) | 57 (24.2) | 15 (33.3) |
Follow-up time, mean ± SD* | 28.45 ± 8.89 | 25.85 ± 8.95 | 21.36 ± 10.47 | 26.69 ± 9.27 | 22.83 ± 10.11 |
Alcohol risk behavior (ALR) and diagnosed alcoholism (ALC) | |||||
ALR at baseline, n (%) | 159 (28.9) | 11 (20.8) | 8 (30.8) | 74 (31.5) | 9 (20.0) |
Incident cases with ALC, n (%) | 2 (0.4) | 1 (1.9) | 0 (0) | 2 (0.9) | 1 (2.2) |
Total cases, n (%) | NA | NA | NA | NA | NA |
Follow-up time, mean ± SD* | 28.81 ± 9.02 | 26.37 ± 8.81 | 21.69 ± 10.81 | 27.06 ± 9.43 | 23.39 ± 10.16 |